Topic: Cancer
Aberrant Cell Fraction Estimation in NxClinical 5.0
NxClinical has very strong visualization tools which is important for cytogeneticists - a reviewer can easily view the allele patterns and estimate % aberrant cells. But NxClinical 5.0 makes this even easier by automatically performing this calculation on a per event basis. The software also uses a user-defined threshold to mark events as mosaic or not. The software looks at event-specific aberrant cell fraction using both the Log R value as well as BAF (where available). This approach uses platform-dependent scaling so that the correct calculation can be applied to samples from multiple platforms (e.g. ThermoFisher, Illumina, CNV from NGS).
Copy Number and Loss of Heterozygosity Analysis in Tumors
The 2019 Tumor Profiling: Methods and Protocols book is out and we are particularly excited about the Whole-Genome Single Nucleotide Polymorphism Microarray for Copy Number and Loss of Heterozygosity Analysis chapter! Read more.
Southern California Regional Cytogenetics & Molecular Genetics Meeting Proves to be Big Success
The Southern California Regional Cytogenetics & Molecular Genetics Meeting last week was a big success. Some of the biggest names in the space attended and were able to provide feedback on the unique cases that were presented, what tools seem to work best, and how they would approach the issue.
Another Successful ACC Conference
Another successful ACC event. The ACC conference is a great way to really connect with the thought leaders in the cytogenetic community. Read this blog to get the conference highlights!
Welcome back to everyone who visited us at AMP 2017
We showed the benefits of an integrated review of CNV, AOH, and SNV using our NxClinical software which handles both array and NGS data in a single system.
Cancer statistics in males and females
The US cancer statistics for 2017 were published early this year. Cancer statistics comparison between males and females seems to be the most interesting one.
Cancer Liquid Biopsy Gains Momentum
Cancer screening for circulating tumor DNA (ctDNA) in the bloodstream, Liquid Biopsy, is a fast growing market.
Patent application for methods for prognosticating brain tumors uses Nexus Copy Number and TCGA Premier
Cedar Sinai Medical Center in Los Angeles, CA has filed a patent for a method for prognosticating patient survival based on the ZEB1 gene. The application also describes methods for selecting therapies based on analysis of ZEB1 and several other genes.
Nexus Copy Number – Casting a Wide Net
Nexus Copy Number has been used to work on a variety of organisms, including canines, monkeys, plants, humans, and more. View these highlighted publications.
BioDiscovery invited to exhibit NxClinical software with Philips at AMP 2016
BioDiscovery was invited as a partner to exhibit its NxClinical software with Philips at the American Molecular Pathology (AMP) Annual Conference. BioDiscovery's NxClinical has been an established software tool in clinical labs for copy number variants analysis and reporting.
- BioDiscovery, Inc.
- 715 North Douglas Street
- El Segundo, CA 90245
- Tel: (310) 414-8100
- Fax: (310) 414-8111
© 2018 BioDiscovery. All rights reserved.